Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin in HER2-expressing CRPC
NCT06227156Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in castration-resistant prostate cancer (CRPC), sponsored by RemeGen. Started Apr 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06227156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227156.